A Phase 1 interventional study of ipilimumab and nivolumab in Tumor, sponsored by Bristol-Myers Squibb. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-24.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 21 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Part 1 Arms A and B: Melanoma
Part 1 Arm A:Advanced/mUC - Participants with histologically or cytologically confirmed urothelial carcinoma.
Part 1 Arm A: Advanced HCC
Part 2 Arm A: Metastatic NSCLC
Part 2 Arm B: Advanced or Metastatic RCC
Exclusion Criteria:
Part 1 Arm A: Advanced HCC
Part 2 Arm A: NSCLC
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
metastatic Melanoma (mM), metastatic Urothelial Carcinoma (mUC), and advanced Heptocellular Carcinoma (HCC)
Drug: ipilimumab · Drug: nivolumab · Drug: ENHANZE (rHuPH20)
metastatic Melanoma (mM)
Drug: ipilimumab · Drug: nivolumab
metastatic non small cell lung cancer (NSCLC)
Drug: ipilimumab · Drug: ENHANZE (rHuPH20) · Drug: nivolumab
advanced or metastatic renal cell carcinoma (RCC)
Drug: ipilimumab · Drug: ENHANZE (rHuPH20) · Drug: nivolumab
Specified Dose on Specified Days
Also known as: (BMS-734016)
Specified Dose on Specified Days
Also known as: (BMS-936558)
Specified Dose on Specified Days
Specified Dose on Specified Days
Also known as: (BMS-986298)
Part 1 Arm A: Average concentration of ipilimumab (Cavg21d)
Time frame: Day 21
Part 1 Arm A: Area under the concentration in ipilimumab AUC(0-21d)
Time frame: Day 21
Part 1 Arm A: Maximum observed serum concentration of ipilimumab (Cmax)
Time frame: Up to 21 days
Part 1 Arm A: Observed concentration of ipilimumab at 21 days post dose (C21d)
Time frame: Day 21
Part 1 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)
Time frame: Up to 21 days
Part 2 Arm A: Average concentration in ipilimumab (Cavg42d)
Time frame: Day 42
Part 2 Arm A: Area under the concentration in ipilimumab AUC(0-42d)
Time frame: Day 42
Part 2 Arm A: Maximum observed serum Concentration of Ipilimumab (Cmax)
Time frame: Up to 42 days
Part 2 Arm A: Observed concentration in ipilimumab (C42d)
Time frame: Day 42
Part 2 Arm A: Time of maximum observed concentration in ipilimumab (Tmax)
Time frame: Up to 42 days
Part 2 Arm B: Average concentration of Ipilimumab at 21 days post dose (Cavg21d)
Time frame: Day 21
Part 2 Arm B: Area Under the Concentration in Ipilimumab AUC(0-21d)
Time frame: Day 21
Part 2 Arm B: Maximum observed serum Concentration in Ipilimumab (Cmax)
Time frame: Up to 21 days
Part 2 Arm B: Observed concentration of ipilimumab at 21 days post dose (C21d)
Time frame: Day 21
Part 2 Arm B: Time of maximum observed concentration in Ipilimumab (Tmax)
Time frame: Up to 21 days
Part 1 Arm B: Average concentration of ipilimumab without rHuPH20 (Cavg21d)
Time frame: Day 21
Part 1 Arm B: Area under the concentration in ipilimumab without rHuPH20 AUC(0-21d)
Time frame: Day 21
Part 1 Arm B: Maximum observed serum concentration of ipilimumab without rHuPH20 (Cmax)
Time frame: Up to 21 days
Part 1 Arm B: Observed concentration of ipilimumab without rHuPH20 at 21 days post dose (C21d)
Time frame: Day 21
Part 1 Arm B: Time of maximum observed concentration in ipilimumab without rHuPH20 (Tmax)
Time frame: Up to 21 days
Incidence of adverse events (AE's)
Time frame: Up to 2.5 years
Incidence of serious adverse events (SAEs)
Time frame: Up to 5 years
Incidence of AE's leading to discontinuation
Time frame: Up to 2.5 years
Incidence of death
Time frame: Up to 2.5 years
Incidence of laboratory abnormalities
Time frame: Up to 2.5 years
Instance of Anaphylactic occurring within 2 days of study drug administration
Time frame: Up to 2.5 years
Instance of hypersensitivity occurring within 2 days of study drug administration
Time frame: Up to 2.5 years
Incidence of hypersensitivity occurring within 2 days of study drug administration
Time frame: Up to 2.5 years
Incidence of infusion reactions occurring within 2 days of study drug administration
Time frame: Up to 2.5 years
Incidence of injection occurring within 2 days of study drug administration
Time frame: Up to 2.5 years
Percentage of participants who develop anti-ipilimumab antibodies
Time frame: Up to 2.5 years
Percentage of participants who develop anti-nivolumab antibodies
Time frame: Up to 2.5 years
Percentage of participants who have developed neutralizing antibodies
Time frame: Up to 2.5 years
Ran from Jun 2020 to primary completion in Jan 2021, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ipilimumab · Nivolumab